Keyphrases
Randomized Phase II Trial
100%
Glucagon-like
100%
Short Bowel Syndrome
100%
Phase II Trial
100%
Wet Weight
16%
Intestinal Absorption
16%
Treatment Duration
16%
Abdominal Pain
16%
Vomiting
8%
Therapeutic Potential
8%
Dizziness
8%
Abdominal Distension
8%
Safety Analysis
8%
Injection Site Reaction
8%
Second Dose
8%
Catheter-related Infections
8%
Cough
8%
Pharma
8%
Absolute Change
8%
Zealand
8%
Treatment-related Adverse Events
8%
Metabolic Balance
8%
Patient-completed
8%
Stomata
8%
Intestinal Adaptation
8%
Balance Study
8%
Unknown Origin
8%
Phase III Clinical Trial
8%
Single Center
8%
Decreased Appetite
8%
Stoma Complications
8%
Intention-to-treat
8%
Change from Baseline
8%
Subcutaneous Injection
8%
Polyuria
8%
Adjusted Means
8%
Nausea
8%
Peripheral Edema
8%
Healthcare Professionals
8%
Washout Period
8%
Serious Adverse Events
8%
Per-protocol Analysis
8%
Catheter-related Sepsis
8%
Statistician
8%
Number of Patients
8%
Pharmacology, Toxicology and Pharmaceutical Science
Glepaglutide
100%
Catheter Occlusion
8%